Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today
announced that President and CEO, Igor Gonda, will present at the
Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27,
2016, at 1:00 p.m. ET. The event will be held at the Sofitel New York in
New York, New York.
Interested parties can access a live audio webcast and slide
presentation at www.aradigm.com.
An archived presentation will be available on the Company's Web site for
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm is currently in Phase
3 development of Pulmaquin® (an investigational proprietary formulation
of ciprofloxacin for inhalation) for the treatment of non-cystic
fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations
are also product candidates for treatment of patients with cystic
fibrosis and non-tuberculous mycobacteria, and for the prevention and
treatment of high threat and bioterrorism infections, such as inhaled
tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005539/en/
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media